Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 270

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 270
---

MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  18.      Research              

                                          Year ended                      Year ended                      Year ended                  
                                          October 31,                     October 31,                     October 31,                 
                                          2024                            2023                            2022                        
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and                            $                  747,026      $                1,159,147      $                2,380,942  
  Salaries, regulatory, professional                         542,615                         469,667                         666,125  
  Share-based compensation                                   132,502                          45,870                         213,299  
  Reimbursements (Note 6)                                   ( 50,319                       ( 141,409                       ( 194,205  
  Amortization                                                10,984                          10,954                          14,830  
  Total research and development,         $                1,382,808      $                1,544,229      $                3,080,991  

  19.      Subsequent  

  During November 2024, the Company sold all the shares of Polyrizon, for total proceeds of $ 82,961.  

  During the period between December 13, 2024 and December 26, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants, were exercised into 310,388 common shares, for gross p...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

F-37